A SINGLE BLIND RANDOMIZED CONTROLLED TRIAL TO COMPARE EFFECTIVENESS OF ORAL ITRACONAZOLE PULSE THERAPY V/S ORAL ITRACONAZOLE PULSE THERAPY PLUS 1064 nm Q-SWITCHED Nd: YAG LASER V/S 1064 nm Q-SWITCHED Nd: YAG LASER FOR THE TREATMENT OF ONYCHOMYCOSIS WITH SPECIES STUDY IN A TERTIARY HEALTH CARE CENTRE

Dr Prasenjeet Mohanty0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients having one or more toenail and/or fingernail fungal infections of the following types: distal subungual onychomycosis, proximal subungual onychomycosis, superficial white/black onychomycosis, endonyx onychomycosis, total dystrophic type onychomycosis or mixed onychomycosis.
•2.Patients with diabetes mellitus, immunocompromised patients, and organ transplant patients will be included, although we consider that these patient groups success rates could be considerably less.

•1.Patients who used systemic antifungal or isotretinoin within 6months.
•2.Permanent or semi-permanent discoloration of the nail plate (e.g. topical therapeutics, cosmetics or professional dye exposure) as they can cause various physiological changes to the nail plate in addition to discoloration.
•3.Subungual hematoma, nevoid subungual formation, bacterial nail infections, and concomitant nail disorders such as psoriasis of nail plate, lichen planus and atopic dermatitis.
•4.Fungal infections of other body parts.
•5.Any generalized skin disease.
•6.Pregnancy.
•7.Patients having liver or renal disease.

发起方

Dr Prasenjeet Mohanty